© 2021 MJH Life Sciences and Pharmacy Times. All rights reserved.
© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
September 11, 2014
The FDA has expanded the approval for enzalutamide (Xtandi) to include the treatment of men with chemotherapy-naive metastatic castration-resistant prostate cancer.
October 01, 2013
Pertuzumab (Perjeta) in combination with trastuzumab and chemotherapy has become the first FDA-approved neoadjuvant treatment for patients with breast cancer.